Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 456582, 13 pages
http://dx.doi.org/10.1155/2015/456582
Research Article

Activation of Endocannabinoid System Is Associated with Persistent Inflammation in Human Aortic Aneurysm

1Department of Cardiac Surgery, University Clinical Centre Bonn, Sigmund-Freud Street 25, 53105 Bonn, Germany
2Institute of Molecular Psychiatry, Life & Brain Center, Sigmund-Freud Street 25, 53105 Bonn, Germany
3Institute of Physiological Chemistry, University Medical Centre of the Johannes Gutenberg University Mainz, Duesbergweg 6, 55128 Mainz, Germany

Received 23 June 2015; Revised 27 August 2015; Accepted 30 August 2015

Academic Editor: Renzhi Han

Copyright © 2015 Christopher Gestrich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Danyi, J. A. Elefteriades, and I. S. Jovin, “Medical therapy of thoracic aortic aneurysms: are we there yet?” Circulation, vol. 124, no. 13, pp. 1469–1476, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. L. F. Hiratzka, G. L. Bakris, J. A. Beckman et al., “2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine,” Catheterization and Cardiovascular Interventions, vol. 76, no. 2, pp. E43–E86, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. N. J. Biery, Z. A. Eldadah, C. S. Moore, G. Stetten, F. Spencer, and H. C. Dietz, “Revised genomic organization of FBN1 and significance for regulated gene expression,” Genomics, vol. 56, no. 1, pp. 70–77, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. B. L. Loeys, U. Schwarze, T. Holm et al., “Aneurysm syndromes caused by mutations in the TGF-beta receptor,” The New England Journal of Medicine, vol. 355, no. 8, pp. 788–798, 2006. View at Google Scholar
  5. V. T. Nkomo, M. Enriquez-Sarano, N. M. Ammash et al., “Bicuspid aortic valve associated with aortic dilatation: a community-based study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 2, pp. 351–356, 2003. View at Google Scholar
  6. H. I. Michelena, A. D. Khanna, D. Mahoney et al., “Incidence of aortic complications in patients with bicuspid aortic valves,” Journal of the American Medical Association, vol. 306, no. 10, pp. 1104–1112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Shimizu, R. N. Mitchell, and P. Libby, “Inflammation and cellular immune responses in abdominal aortic aneurysms,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 5, pp. 987–994, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Iida, B. Xu, H. Xuan et al., “Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 4, pp. 718–726, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. F. M. Davis, D. L. Rateri, and A. Daugherty, “Mechanisms of aortic aneurysm formation: translating preclinical studies into clinical therapies,” Heart, vol. 100, no. 19, pp. 1498–1505, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Branchetti, P. Poggio, R. Sainger et al., “Oxidative stress modulates vascular smooth muscle cell phenotype via CTGF in thoracic aortic aneurysm,” Cardiovascular Research, vol. 100, no. 2, pp. 316–324, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. A. W. Y. Chung, H. H. Clarice Yang, M. W. Radomski, and C. Van Breemen, “Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in Marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9,” Circulation Research, vol. 102, no. 8, pp. e73–e85, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. G. M. Longo, W. Xiong, T. C. Greiner, Y. Zhao, N. Fiotti, and B. Timothy Baxter, “Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms,” Journal of Clinical Investigation, vol. 110, no. 5, pp. 625–632, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. R. G. Pertwee, “Cannabinoid pharmacology: the first 66 years,” British Journal of Pharmacology, vol. 147, supplement 1, pp. S163–S171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. T. W. Klein, K. Larsen, L. Lu et al., “The cannabinoid system and immune modulation,” Journal of Leukocyte Biology, vol. 74, no. 4, pp. 486–496, 2003. View at Google Scholar
  15. B. Julien, P. Grenard, F. Teixeira-Clerc et al., “Antifibrogenic role of the cannabinoid receptor CB2 in the liver,” Gastroenterology, vol. 128, no. 3, pp. 742–755, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Wenzel, M. Matthey, L. Bindila et al., “Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 46, pp. 18710–18715, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. G. D. Duerr, J. C. Heinemann, G. Suchan et al., “The endocannabinoid-CB2 receptor axis protects the ischemic heart at the early stage of cardiomyopathy,” Basic Research in Cardiology, vol. 109, no. 4, article 425, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. G. D. Duerr, J. C. Heinemann, S. Dunkel et al., “Myocardial hypertrophy is associated with inflammation and activation of endocannabinoid system in patients with aortic valve stenosis,” Life Sciences, vol. 92, no. 20-21, pp. 976–983, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. R. He, D.-C. Guo, A. L. Estrera et al., “Characterization of the inflammatory and apoptotic cells in the aortas of patients with ascending thoracic aortic aneurysms and dissections,” Journal of Thoracic and Cardiovascular Surgery, vol. 131, no. 3, pp. 671–e2, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Grewal, A. C. Gittenberger-de Groot, M. C. DeRuiter et al., “Bicuspid aortic valve: phosphorylation of c-Kit and downstream targets are prognostic for future aortopathy,” European Journal of Cardio-Thoracic Surgery, vol. 46, no. 5, pp. 831–839, 2014. View at Google Scholar
  21. W. F. Johnston, M. Salmon, N. H. Pope et al., “Inhibition of interleukin-1β decreases aneurysm formation and progression in a novel model of thoracic aortic aneurysms,” Circulation, vol. 130, supplement 1, no. 11, pp. S51–S59, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Carta, S. Smaldone, L. Zilberberg et al., “p38 MAPK is an early determinant of promiscuous Smad2/3 signaling in the aortas of fibrillin-1 (Fbn1)-null mice,” The Journal of Biological Chemistry, vol. 284, no. 9, pp. 5630–5636, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. H. Meng, C. Tian, L. Liu, L. Wang, and Q. Chang, “Elevated expression of connective tissue growth factor, osteopontin and increased collagen content in human ascending thoracic aortic aneurysms,” Vascular, vol. 22, no. 1, pp. 20–27, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Daugherty, M. W. Manning, and L. A. Cassis, “Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice,” Journal of Clinical Investigation, vol. 105, no. 11, pp. 1605–1612, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. T. P. Theruvath, J. A. Jones, and J. S. Ikonomidis, “Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch,” Journal of Cardiac Surgery, vol. 27, no. 1, pp. 81–90, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. J. H. Wang, K. Eguchi, S. Matsumoto et al., “The omega-3 polyunsaturated fatty acid, eicosapentaenoic acid, attenuates abdominal aortic aneurysm development via suppression of tissue remodeling,” PLoS ONE, vol. 9, no. 5, Article ID e96286, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Pacher, S. Bátkai, and G. Kunos, “Blood pressure regulation by endocannabinoids and their receptors,” Neuropharmacology, vol. 48, no. 8, pp. 1130–1138, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Di Marzo, F. Piscitelli, and R. Mechoulam, “Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes,” Handbook of Experimental Pharmacology, vol. 203, pp. 75–104, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Rylski, P. Blanke, M. Siepe et al., “Results of high-risk endovascular procedures in patients with non-dissected thoracic aortic pathology: intermediate outcomes,” European Journal of Cardio-Thoracic Surgery, vol. 44, no. 1, pp. 156–162, 2013. View at Publisher · View at Google Scholar · View at Scopus